摘要
目的回顾性研究晚期非小细胞肺癌患者放疗前后血清CEA、CYFAR21—1、SCC、CA125的水平变化,探讨血清肿瘤标志物的改变及与放疗近期疗效的关系。方法常规检查205例经确诊的晚期非小细胞肺癌患者放疗前、后血清CEA、CYFAR21—1、SCC、CA125等肿瘤标志物的水平(应用电化学发光法),同时评估放疗的近期疗效,分析肿瘤标志物的变化及与近期疗效的关系。结果205例患者放疗后近期有效113例,总有效率为55.1%。此113例患者放疗后血清CEA、CYFAR21—1、SCC、CA125水平均较放疗前发生了明显下降(t=3.224,2.896,3.137,3.219,P〈0.05),其中Ⅲ期及Ⅳ期患者血清肿瘤标志物CEA、CYFAR21—1、SCC、CA125放疗后与放疗前比较,差异均有统计学意义(Ⅲ期:t=2.484,2.445,2.148,2.109,P〈0.05;Ⅳ期:t=2.072,2.857,2.277,2.436,P〈0.05);而放疗后近期非有效的92例患者中,放疗后血清肿瘤标志物较放疗前明显上升(t=2.224,2.005,2.261,2.545,P〈0.05)。放疗后肿瘤标志物降低组的近期疗效明显好于肿瘤标志物升高组,差异有统计学意义(χ2=80.001,P〈0.01)结论血清肿瘤标志物CEA、CYFAR21—1、SCC、CA125水平或可用于晚期非小细胞肺癌患者放疗后的近期疗效评估。
Objective To investigate the change of the serum levels of CEA, CYFAR21-1, SCC, CA125 in advanced non-small cell lung cancer.patients before and after radiotherapy retrospectively and to explore the relationship between the change of serum tumor markers and the short-term efficacy of radiotherapy. Methods The serum levels of CEA, CYFAR21-1, SCC, CA125 in 205 cases with advanced non-small cell lung cancer'were detected ( by electro-chemiluminescence immunoassay method) before and after radiotherapy, and the short-term efficacy of radiotherapy was assessed (RECIST 1.1 edition) at the same time. The changes in tumor markers and the short-term efficacy were analyzed. Results Totally 113 patients achieved response of short-term efficacy after radiotherapy, and the effective rate of the short-term efficacy was 55.1%. Among these 113 patients, the serum levels of tumor markers decreased significantly after radiotherapy( t = 3. 224, 2. 896, 3. 137, 3. 219, P 〈 0. 05 ). The serum levels of tumor markers in patients with stage and decreased after radiotherapy ( t =2. 484, 2. 445,2. 148, 2. 109, P 〈0.05 ;t =2. 072, 2. 857, 2. 277, 2. 436, P 〈0. 05). Among 92 patients who did not achieve response of short-term efficacy, the serum level of tumor markers increased significantly after radiotherapy( t = 2. 224, 2. 005, 2. 261, 2. 545, P 〈 0.05 ). For the patient who achieved response of radiotherapy with tumor markers decreased, the short-term efficacy was significantly better than the group of which tumor maker increased (χ2 = 80. 001, P 〈 0. 01 ). Conclusions The serum levels of CEA, CYFAR21-1, SCC,CA125 can be used for assessment of short-term efficacy after radiotherapy in advanced non-small cell lung cancer patients.
出处
《中华放射医学与防护杂志》
CAS
CSCD
北大核心
2013年第3期290-293,共4页
Chinese Journal of Radiological Medicine and Protection